Edition:
United Kingdom

Toni Clarke

Jeff Mason is a White House Correspondent for Reuters and the 2016-2017 president of the White House Correspondents’ Association. He was the lead Reuters correspondent for President Barack Obama's 2012 campaign and interviewed the president at the White House in 2015. Jeff has been based in Washington since 2008, when he covered the historic race between Obama, Hillary Clinton and John McCain. Jeff started his career in Frankfurt, Germany, where he covered the airline industry before moving to Brussels, Belgium, where he covered the European Union. He is a Colorado native, proud graduate of Northwestern University and former Fulbright scholar.

Twitter handle: @jeffmason1

19 Oct 2017

FDA approves Gilead cancer gene therapy; price set at $373,000

U.S. regulators approved on Wednesday a new therapy for a type of lymphoma, which was developed by Gilead Science Inc's Kite Pharma, marking the second approval for this potentially revolutionary approach to fighting cancer.

19 Oct 2017

Novo Nordisk takes aim at Eli Lilly with U.S. backing of new diabetes drug

WASHINGTON/COPENHAGEN Denmark's Novo Nordisk will take aim at Eli Lilly in the growing diabetes market after an advisory panel to the U.S. Food and Drug Administration (FDA) gave the green light to its semaglutide drug.

16 Oct 2017

Novo Nordisk diabetes drug works; no heart risk-FDA review

Novo Nordisk A/S's closely watched diabetes drug semaglutide is effective, caused no heart risk, and carried only limited risk of sight problems, a preliminary review by the U.S. Food and Drug Administration concluded on Monday, sending the company's shares up 4 percent.

12 Oct 2017

FDA panel backs gene therapy for rare form of blindness

Spark Therapeutics Inc's experimental gene therapy for a rare form of blindness improves vision and should be approved, advisers to the Food and Drug Administration concluded on Thursday, paving the way for the first U.S. gene therapy for an inherited disease.

10 Oct 2017

Food and drug chief Gottlieb skirts health secretary talk, says most effective at FDA

U.S. Food and Drug Administration Commissioner Scott Gottlieb, considered a potential successor to recently departed Health and Human Services Secretary Tom Price, said on Tuesday he believed he could best serve the Trump administration in his current role.

10 Oct 2017

Food and drug chief Gottlieb skirts health secretary talk, says most effective at FDA

Oct 10 U.S. Food and Drug Administration Commissioner Scott Gottlieb, considered a potential successor to recently departed Health and Human Services Secretary Tom Price, said on Tuesday he believed he could best serve the Trump administration in his current role.

10 Oct 2017

Spark gene therapy improves vision, at least in short term: FDA

Spark Therapeutics Inc's experimental gene therapy for a rare inherited form of blindness improves vision, though it is unclear whether the benefit lasts over time, according to a preliminary review by the U.S. Food and Drug Administration.

02 Oct 2017

FDA moves to smooth path for complex generic drugs

WASHINGTON The U.S. Food and Drug Administration on Monday announced a series of measures designed to speed to market generic versions of complex drugs such as Mylan NV's emergency EpiPen in an effort to address the rising cost of pharmaceuticals.

28 Sep 2017

PTC Therapeutics Duchenne drug may work, data inconclusive: FDA panel

PTC Therapeutics Inc's experimental drug to treat Duchenne muscular dystrophy, a devastating degenerative disease that mostly affects young boys, may work but the company will need to do more work to prove it, an advisory panel to the U.S. Food and Drug Administration concluded on Thursday.

26 Sep 2017

FDA pours cold water on PTC Therapeutics' Duchenne drug application

PTC Therapeutics Inc has failed to supply persuasive evidence that its experimental drug to treat a form of Duchenne muscular dystrophy is effective, the U.S. Food and Drug Administration said on Tuesday, dealing a blow to the company's years-long effort to bring the drug to market.

  • Europe
  • U.S.
  • Asia
  • Sectors
Stock Search
FTSE 100 7,523.04 -19.83 -0.26%
DAX 12,990.10 -- --%
CAC 40 5,368.29 + 0.00 +0.00%
TR Europe 185.54 -0.31 -0.17%
GBP/USD 1.3112 -0.34%
GBP/EUR 1.1100 +0.01%
EUR/USD 1.1812 -0.32%
Gold 1,286.90 +0.00 +0.00%
Oil 51.51 +0.22 +0.43%
Corn 348.25 -0.75 -0.21%